Inclusion Criteria:

1. Adult participants ≥18 to <70 years of age at Screening

2. Long COVID with neurological symptoms as defined below:

1. Current symptoms of at least fatigue and neurocognitive impairment that began
or worsened after an index SARS-CoV-2 infection that occurred at least 3 months
prior to screening. Index SARS-CoV-2 infection is defined as either: 1) an
episode of COVID-19 with a positive nucleic acid or antigen test during acute
illness, as documented in the medical record, or 2) a documented clinical
diagnosis of COVID-19, which can be based on a patient-reported positive test
for COVID-19. Note that a documented diagnosis of Long COVID is not required
for inclusion.

2. Symptoms cannot be explained by any concomitant condition or diagnosis, in the
opinion of the investigator.

3. Symptom duration for at least 3 months.

3. PROMIS Cognitive Function SF8a T score ≤ 40 (≥ 1 SD below normative mean) after
rounding to nearest integer. If the T score is marginally exclusionary, a subject
may be allowed following discussion between the investigator and BioVie Medical
Monitor.

4. PROMIS Fatigue SF13a T score ≥ 50 (≥ normative mean) after rounding to nearest
integer.

5. If taking medications for glycemic control at the time of Screening, must be stable
on the current dosage and form for ≥ 3 months prior to randomization and expected to
remain stable throughout participation in the study.

6. Willing and able to provide voluntary written informed consent, complete the
surveys, clinical assessments, and participate in the virtual follow-up visit at the
end of the 4-week follow-up period (the End of Study visit).

7. Agree to maintain any other regular medications at current doses for the duration of
the trial (except for essential need of new medication or dose change, as prescribed
by a physician)

8. Females taking hormone replacement therapy (HRT) must have maintained a stable
regimen for at least 6 months prior to randomization and agree to continue the
regimen until completing the final safety assessment in Week 16.

9. Must meet one of the following criteria:

1. Females: Must be postmenopausal (postmenopausal status must be confirmed as no
menstrual bleeding for >1 year, or via a follicle stimulating hormone [FSH]
assessment at Screening), or have been surgically sterilized (e.g.,
hysterectomy, bilateral oophorectomy, or tubal ligation) at least 6 months
prior to Screening or agree to highly effective contraception, such as double
barrier methods (e.g. condom with spermicide, IUD with spermicide). Oral
contraceptives alone are insufficient.

2. Males: If not vasectomized, must be abstinent or agree to use a double barrier
contraception method and indicate that their partner is using highly effective
birth control (as defined in 11a) until the end of the study.

10. Willing to allow collection of blood for DNA methylation analysis.

11. Participant has native-level proficiency in English.

Exclusion Criteria:

1. Positive SARS-CoV-2 nucleic acid or rapid Antigen test in the past 28 days

2. Received a vaccination for COVID-19 or influenza within 2 weeks of randomization

3. Previous admission to the intensive care unit for COVID-19-related symptoms and/ or
if intubated (i.e. mechanical ventilation) for COVID-19 care.

4. Prior or active unstable or progressive major psychiatric or neurologic condition
that may impact ability to determine a treatment effect and is not related to
SARS-CoV-2 infection, including, but not limited to, the following examples as
determined by the investigator:

1. Progressive neurodegenerative disease, such as Alzheimer's disease, Parkinson's
disease, etc.

2. Past traumatic brain injury occurrence still associated with active
post-concussive symptoms

3. History of epilepsy or seizure disorder requiring ongoing treatment, or any
seizure or loss of consciousness within 12 months prior to Screening

4. Post-stroke deficits that may interfere with assessment, such as language or
communication difficulties, aphasia, etc.

5. Formal thought disorders, such as schizophrenia, psychotic bipolar disorder
etc.

6. Any neuropsychiatric or neurologic disorder uncontrolled for the previous six
months or that may interfere with assessment, at discretion of the investigator

7. Functional neurologic disorder

8. Major Depressive Disorder not on stable treatment for at least 3 months prior
to Screening and not planning to stay on a stable dose through the study, or a
PHQ-2 score ≥ 3. (If the PHQ-2 score is ≥3 the investigator should discuss with
the BioVie Medical Monitor to confirm eligibility)

9. Premenstrual dysphoric disorder (PMDD)

5. In the opinion of the investigator any physical, cognitive (for example intellectual
disability or pre-dementia), or language impairments sufficient to adversely affect
data derived from cognitive assessments.

6. Diagnosed reading disability or dyslexia, or clinically significant learning
disorder by history.

7. Documented attention deficit hyperactivity disorder (ADHD) being treated with
psychostimulants. Individuals diagnosed with ADHD being treated with non-stimulants
must be stable on the current dosage for ≥ 3 months prior to randomization and
expected to remain stable throughout participation in the study.

8. Known active bacterial, fungal, viral, or other infection besides SARS-CoV-2
requiring treatment within 28 days prior to randomization and meeting criteria for
systemic involvement upon review by the site investigator. Note: Mild or limited
infections such as uncomplicated urinary tract or yeast infections, sexually
transmitted infections, and mild dermatophyte infections may be reviewed with the
study investigator but are not exclusionary.

9. Diagnosis of narcolepsy.

10. History of obstructive sleep apnea unless the participant is compliant with
prescribed treatment (e.g., CPAP or BiPAP therapy) as confirmed by medical records
or clinician assessment.

11. History of congestive heart failure suspected or known dissecting aneurysm, recent
systemic or pulmonary embolus or myocardial infarction (≤ 6 months), severe valvular
heart disease, ventricular aneurysm, active or suspected myocarditis or
pericarditis, thrombophlebitis or intracardiac thrombi.

12. Electrocardiogram with clinically significant findings as assessed by the
Investigator. Note: Below are the examples of clinically significant ECG
abnormalities:

1. Previous documented evidence of myocardial infarction or recent significant
change in the resting ECG suggesting infarction or other acute cardiac events.

2. Current symptoms of coronary insufficiency (i.e. angina pectoris and/or ST
segment depression on ECG).

3. Evidence of uncontrolled atrial or frequent or complex ventricular ectopy, or
myocardial conduction defect which would increase the risk of syncope (for
example, second degree or higher A-V block).

4. QT prolongation (QTcF >450 msec (male) or >470 msec (female) [If QTcF is
marginally above these values, a subject may still be allowed on a case-by-case
basis following discussion between the investigator and medical monitor].

13. History of moderate or severe chronic obstructive pulmonary disease or moderate or
severe asthma.

14. History of chronic fatigue syndrome, fibromyalgia, or postural orthostatic
tachycardia syndrome (POTS) prior to index COVID-19 infection

15. Known diagnosis of chronic Lyme disease or tertiary syphilis with persistent
symptoms, sequelae, or related therapy.

16. History of human immunodeficiency virus (1 and 2), chronic hepatitis B, or hepatitis
C. Participants with hepatitis C who had spontaneous resolution or received
successful curative treatment (e.g., HARVONI® [ledipasvir/sofosbuvir]) with
documentation of undetectable viral load for at least 3 months may be allowed.

17. Screening lab abnormalities that may indicate alternate explanation for fatigue or
cognitive impairment, such as severe anemia, hypocalcemia, or thyroid dysfunction.

18. Has any of the following laboratory findings at Screening (marginally exclusionary
lab values that appear to be artifactual or likely, in the investigator's opinion,
to represent a transient and benign condition may still be allowed)

1. Alanine aminotransferase (ALT) > 2 × upper limit of normal (ULN), aspartate
aminotransferase (AST) > 2 × ULN, or history of clinically significant liver
disease, in the investigator's medical judgment.

2. Hemoglobin ≤ 10 g/dL if female, ≤11.5 g/dL if male

3. International normalized ratio (INR) > 1.5 if not on anticoagulant medication;
if the participant is on anticoagulant medication, the anticoagulant medication
should be optimized and on a stable dose for ≥ 4 weeks prior to Screening.

4. Creatinine clearance (CKD-EPI Creatinine Equation 202139 of <45 mL/min).

5. Untreated diabetes with hemoglobin A1c > 9.0.

19. Pregnant or lactating.

20. History of:

1. Cancer requiring systemic therapy within the last 5 years, except for localized
basal cell carcinoma of the skin or in-situ cervical cancer successfully
treated with surgical excision or

2. Current unstable medical illness which would interfere with interpretation of
the data.

3. Recent thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism,
etc.) within 6 months prior to randomization.

21. History of alcohol use disorder or substance use disorder within 12 months of
Screening as defined by the Diagnostic and Statistical Manual of Mental Disorders-5.

22. Suicidality risk:

1. Per C-SSRS: History of active suicidal thoughts (answers 'Yes' on questions 4
or 5 on the C-SSRS) in the 6 months prior to Screening or;

2. History of a suicide attempt in the previous 2 years or;

3. Participant is at serious suicide risk in the investigator's clinical judgment.

23. Lifetime history of breast cancer.

24. Participant is unwilling to not begin, resume, or increase the dose of any form of
cognitive training or cognitive-enhancing supplements until the end of the active
intervention phase of the trial. Cognitive training is any non-pharmacological
intervention that participants started intending to enhance their cognition. A
cognitive-enhancing supplement is any non-prescription compound being taken by
participants with the goal of enhancing their cognition.

25. Participant is unwilling to refrain from the use of prohibited medications for the
duration of the study and the use of restricted medications within 12 hours prior to
assessments.

26. Autoimmune diseases are exclusionary only if the participant is receiving or likely
to require initiation of immunomodulatory treatment that would confound the
interpretation of the study data during the participant's participation in this
study.

27. Requirement for supplemental oxygen at the time of screening, unless the participant
has been on a stable supplemental oxygen regimen for at least 3 months prior to
screening.

28. Received investigational agents as part of a separate study within 30 days prior to
the screening visit or 90 days for biologics, prior to the screening visit.

29. Received a direct-acting antiviral agent for COVID infection within the past 2
weeks, or tumor necrosis factor (TNF) inhibitors within the past 90 days prior to
the screening visit.

30. Received systemic or intraarticular steroids within 28 days prior to randomization.
An oral corticosteroid regimen of no more than 7 days is allowed within 28 days
prior to randomization. Allowable regimens can be a tapered regimen or, if a tapered
regimen is not required, a regimen where single daily doses do not exceed 20 mg/day.

31. Any medical intervention, including surgery planned to occur during the study, that,
in the investigator's opinion, would impede or confound study assessments.

32. Participants who are relatives of the sponsor or sponsor representatives are to be
excluded from screening and participation. Relatives of study site personnel may not
participate at the site where a relative is employed or otherwise affiliated with
the site.

33. Participants taking naltrexone at a dose > 4.5mg/day. Participants on a dose of ≤
4.5 mg/day must be stable on the current dosage for ≥ 3 months prior to
randomization and expected to remain stable throughout participation in the study.

34. Use of or requirement for potent CYP3A4 inhibitors-including clarithromycin,
erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, or verapamil, within
14 days of randomization or within 5 half-lives of the drug, whichever is shorter.

35. Confirmed positive urine drug screen for amphetamine, barbiturates, cocaine and
metabolites, methadone, methamphetamines, MDMA, opiates, oxycodone or phencyclidine.
Note -THC and benzodiazepines are not exclusionary but have restrictions